Acute Kidney Injury | Human Biospecimens online

Acute Kidney Injury

Use the menu on the left side to filter for your ideal biospecimen

Acute Kidney Injury (AKI), classified under the ICD-10 code N17, is a sudden episode of kidney failure or damage that occurs within a few hours or days. This critical condition causes a buildup of waste products in the blood and hampers the kidneys' ability to maintain fluid balance in the body.

Show rows
|< < of > >|

Acute Kidney Injury not only poses an immediate threat to the patients' health but also significantly increases the risk of developing chronic kidney disease (CKD), potentially leading to long-term renal damage and other serious health complications, including renal cancer.

AKI can result from various causes, including severe infections, dehydration, exposure to nephrotoxic agents, and major surgeries that reduce blood flow to the kidneys. Early detection and prompt treatment are essential to prevent permanent kidney damage and improve patient outcomes. However, the pathophysiology of AKI is complex and multifactorial, necessitating extensive research to fully understand its mechanisms and implications.

Research Advancements in AKI

Research in acute kidney injury is crucial for developing effective treatments and improving patient outcomes. Some key areas of AKI research include:

1. Pathophysiology and Mechanisms of AKI: Understanding the underlying mechanisms that cause kidney injury is essential for developing targeted therapies. Researchers are investigating the roles of inflammation, oxidative stress, and ischemia-reperfusion injury in the development of AKI.

2. Biomarkers for Early Detection: Identifying reliable biomarkers that can detect AKI at an early stage is critical for timely intervention. Current research focuses on discovering novel biomarkers in blood and urine that can predict AKI onset and monitor its progression.

3. Novel Therapeutic Approaches: Developing new drugs and therapies to treat AKI is a primary focus of research. This includes exploring the potential of anti-inflammatory agents, antioxidants, and regenerative medicine approaches such as stem cell therapy to repair damaged kidney tissue.

4. Prevention and Management: Research is also focused on identifying strategies to prevent AKI, particularly in high-risk populations such as patients undergoing major surgery or those with sepsis. Effective management strategies are essential to mitigate the impact of AKI and reduce the risk of progression to CKD.

Central BioHub's Commitment to AKI Research

At Central BioHub, we are committed to advancing AKI research by providing high-quality, accessible biosamples essential for studying AKI and its progression. 

Sample Specifications for AKI Research

ICD-10 Code: We offer AKI research samples with ICD-10 classification N17 that give researchers access to clinically relevant and specific cases of acute kidney injury.

Matrix: We provide a diverse range of matrices, including plasma, serum, and urine, to support multifaceted studies into AKI and related kidney diseases.

Why Choose Central BioHub for AKI Research?

Our biospecimens are sourced from well-characterized patient cohorts, ensuring high-quality samples that provide valuable insights into AKI. Each sample is selected for its clinical relevance, supporting robust and impactful research.

To meet the specific needs of researchers, Central BioHub offers advanced search options for procuring AKI samples. Researchers can apply filters and select samples, making it easy to find the samples needed for their studies.

By partnering with Central BioHub, researchers can leverage our extensive collection of AKI biospecimens to advance their studies and make groundbreaking discoveries. Together, we can contribute to the development of new treatments and management strategies for AKI, improving the lives of patients worldwide.

Explore our extensive collection of AKI biospecimens today and take a pivotal step toward unlocking new discoveries in kidney disease treatment and management. Our commitment to quality, diversity, and support for the scientific community makes Central BioHub the ideal source for your research needs. Together, we can make a significant impact on the lives of those affected by AKI.

Join us in the pursuit of new discoveries and better treatments for AKI. Together, we can make a difference.

Explore advanced search options for procuring Kidney disease samples by clicking Clinical Diagnosis, ICD-10-CM codes, Matrix, and Laboratory Parameters.

By providing high-quality, well-characterized biospecimens, Central BioHub facilitates research into AKI, supporting the development of new treatments and diagnostics that could lead to significant improvements in patient care.
AKI research samples are biological specimens classified under the ICD-10 codes N17+, representing various cases of acute kidney injury. These samples, which include plasma, serum, and urine, are an ideal resource for research purposes where scientists can study the onset, progression, and effects of acute kidney failure and related kidney diseases.
AKI research samples of Central BioHub are stored at -18°C, ensuring their integrity for reliable, high-quality research outcomes by preserving their biological relevance.